1-(4-(benzyloxy)phenyl)prop-2-en-1-one | 1268986-67-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-(4-(benzyloxy)phenyl)prop-2-en-1-one
• 英文别名: 1-(4-benzyloxyphenyl)-2-propen-1-one；1-{4-[(phenylmethyl)oxy]phenyl}-2-propen-1-one；1-(4-Phenylmethoxyphenyl)prop-2-en-1-one
• CAS: 1268986-67-9
• 化学式: C₁₆H₁₄O₂
• 分子量: 238.286
• InChiKey: GEPGKEXSOWDJRH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(4-(benzyloxy)phenyl)prop-2-en-1-one 在 tetrakis(actonitrile)copper(I) hexafluorophosphate 、 (S)-1-(二苯基膦基)-2-[(S)-4-异丙基恶唑啉-2-基]二茂铁 、 platinum on carbon 、 氢气 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 四氢呋喃 为溶剂， 生成 ethyl (2S,5R)-5-(4-phenylmethoxyphenyl)pyrrolidine-2-carboxylate
  参考文献：
  名称：

  铜催化下甘氨酸衍生物的不对称共轭加成

  摘要：

  铜tun敲击：已开发出一种廉价，实用且对环境有益的方法，用于将甘氨酸衍生物对映选择性地添加到α，β-不饱和酮中（参见方案）。通过修改后处理，可以得到缀合物加成产物或环状亚胺。催化剂-底物配合物的溶液结构显示出对整体反应选择性的关键。

  DOI：

  10.1002/anie.201105258
• 作为产物：
  描述：

  1-(4-(benzyloxy)phenyl)prop-2-en-1-ol 在 叔丁基过氧化氢 、 chromium(III) oxide 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 1-(4-(benzyloxy)phenyl)prop-2-en-1-one
  参考文献：
  名称：

  第 2 部分。 Notch-sparing γ-secretase 抑制剂：新型γ-氨基萘醇的研究

  摘要：

  阿尔茨海默病的一种治疗方法是抑制 γ-分泌酶对淀粉样前体蛋白 (APP) 的切割。在我们实验室的一系列研究开始时，发现一系列新型 γ-氨基醇 ( 1 ) 具有 γ-分泌酶抑制活性和 Notch 保留作用。将讨论 γ-氨基醇的新一锅合成以及这些类似物的构效关系 (SAR)。

  DOI：

  10.1016/j.bmcl.2016.03.042

文献信息

• Iron-Catalyzed α-Methylenation of Ketones with<i>N</i>,<i>N</i>-Dimethylacetamide: An Approach for α,β-Unsaturated Carbonyl Compounds
  作者：Yi-Ming Li、Shao-Jie Lou、Qin-Hua Zhou、Lian-Wen Zhu、Long-Feng Zhu、Lei Li

  DOI：10.1002/ejoc.201500189

  日期：2015.5

  this study, we developed a general iron-catalyzed α-methylenation of ketones by using N,N-dimethylacetamide as the one-carbon source. Various ketones, including aryl and alkyl ketones, enones, and dicarbonyl compounds were well tolerated to yield the corresponding α,β-unsaturated carbonyl compounds in the presence of an iron catalyst, peroxides, and N,N-dimethylacetamide under aerobic conditions.

  在这项研究中，我们通过使用 N,N-二甲基乙酰胺作为单碳源开发了一种通用的铁催化酮的 α-甲基化。在有氧条件下，在铁催化剂、过氧化物和 N,N-二甲基乙酰胺的存在下，各种酮，包括芳基和烷基酮、烯酮和二羰基化合物，都具有良好的耐受性，可以产生相应的 α,β-不饱和羰基化合物。
• [EN] PROCESS FOR PREPARING ALPHA-CARBOXAMIDE DERIVATIVES<br/>[FR] PROCÉDÉ DE PRÉPARATION DE DÉRIVÉS ALPHA-CARBOXAMIDES
  申请人：CONVERGENCE PHARMACEUTICALS

  公开号：WO2011029762A1

  公开（公告）日：2011-03-17

  The present application provides a process for the preparation of α-carboxamide pyrrolidine derivatives of formula (I), wherein R1 and R2 are independently hydrogen, C1-6alkyl or C3-6cycloalkylC1-6alkyl; or such R1 and R2, together with the nitrogen to which they are attached, may form an unsubstituted 3-, 4-, 5- or 6-membered saturated ring; X is carbon or nitrogen; n is 0, 1 or 2, wherein when present each R5 is independently selected from the list consisting of C1-3alkyl, halogen, cyano, haloC1-3alkyl, hydroxy, C1-3alkoxy and C1-3haloalkoxy; either R6 or R7 is -O-R8, -OCHR9R8, -NCH2R8 or -(CH2)2R8 wherein the other R6 or R7 is hydrogen or R5; and wherein R8 is a phenyl ring or wherein the phenyl ring is optionally substituted by one or more groups independently selected from the list consisting of C1-3alkyl, halogen, cyano, haloC1-3alkyl, hydroxy, C1-3alkoxy and C1-3haloalkoxy; and R9 is hydrogen or C1-3alkyl.

  本申请提供了一种制备式(I)的α-羧酰胺吡咯烷衍生物的过程，其中R1和R2分别是氢、C1-6烷基或C3-6环烷基C1-6烷基；或者这样的R1和R2，连同它们附着的氮，可以形成未取代的3、4、5或6-成员饱和环；X是碳或氮；n为0、1或2，当存在时，每个R5独立地从C1-3烷基、卤素、氰基、卤代C1-3烷基、羟基、C1-3烷氧基和C1-3卤代烷氧基的列表中选择；R6或R7是-O-R8、-OCHR9R8、-NCH2R8或-(CH2)2R8，另一个R6或R7是氢或R5；其中R8是苯环或苯环可以选择地由一个或多个独立选择的C1-3烷基、卤素、氰基、卤代C1-3烷基、羟基、C1-3烷氧基和C1-3卤代烷氧基基团取代；R9是氢或C1-3烷基。
• PROCESS FOR PREPARING ALPHA-CARBOXAMIDE DERIVATIVES
  申请人：Zajac Matthew Allen

  公开号：US20120226053A1

  公开（公告）日：2012-09-06

  The present application provides a process for the preparation of α-carboxamide pyrrolidine derivatives of formula (I), wherein R 1 and R 2 are independently hydrogen, C 1-6 alkyl or C 3-6 cycloalkylC 1-6 alkyl; or such R 1 and R 2 , together with the nitrogen to which they are attached, may form an unsubstituted 3-, 4-, 5- or 6-membered saturated ring; X is carbon or nitrogen; n is 0, 1 or 2, wherein when present each R 5 is independently selected from the list consisting of C 1-3 alkyl, halogen, cyano, haloC 1-3 alkyl, hydroxy, C 1-3 alkoxy and C 1-3 haloalkoxy; either R 6 or R 7 is —O—R 8 , —OCHR 9 R 8 ,—NCH 2 R 8 or —(CH 2 ) 2 R 8 wherein the other R 6 or R 7 is hydrogen or R 5 ; and wherein R 8 is a phenyl ring or wherein the phenyl ring is optionally substituted by one or more groups independently selected from the list consisting of C 1-3 alkyl, halogen, cyano, haloC 1-3 alkyl, hydroxy, C 1-3 alkoxy and C 1-3 haloalkoxy; and R 9 is hydrogen or C 1-3 alkyl.

  本申请提供了一种制备式(I)的α-羧酰胺吡咯烷衍生物的方法，其中R1和R2分别为氢、C1-6烷基或C3-6环烷基C1-6烷基；或者这样的R1和R2，与它们连接的氮一起，可以形成未取代的3、4、5或6元饱和环；X为碳或氮；n为0、1或2，其中当存在时，每个R5都独立地选自C1-3烷基、卤素、氰基、卤代C1-3烷基、羟基、C1-3烷氧基和C1-3卤代烷氧基的列表；R6或R7为—O—R8、—OCHR9R8、—NCH2R8或—（CH2）2R8，其中另一个R6或R7为氢或R5；R8为苯环或苯环可选择地被一个或多个独立选自C1-3烷基、卤素、氰基、卤代C1-3烷基、羟基、C1-3烷氧基和C1-3卤代烷氧基的基团取代；R9为氢或C1-3烷基。
• New pyridin-3-ylmethyl carbamodithioic esters activate pyruvate kinase M2 and potential anticancer lead compounds
  作者：Yu Zhang、Bin Liu、Xingyu Wu、Ridong Li、Xianling Ning、Yu Liu、Zhenming Liu、Zemei Ge、Runtao Li、Yuxin Yin

  DOI：10.1016/j.bmc.2015.05.041

  日期：2015.8

  Pyruvate kinase M2 (PKM2) is a key protein responsible for cancer's Warburg effect. Activation of PKM2 may alter aberrant metabolism in cancer cells, which suggests PKM2 as a tumor selective therapeutic target. In this paper, the lead compound 8 was first discovered as a new kind of PKM2 activator from a random screening of an in-house compound library. Then, a series of lead compound 8 analogs were designed, synthesized and evaluated for their activation of PKM2 and anticancer activities. 7-Azaindole analog 32 was identified as the most potent PKM2 activator. Compounds with potent enzyme activity also exhibited selective anti-proliferation activity on cancer cell lines HCT116, Hela and H1299 compared with non-tumor cell line BEAS-2B. The structure-activity relationships of these compounds were supported by molecular docking results. Preliminary pharmacological studies also showed that compound 32 arrests the cell cycle at the G2/M phase in HCT116 cell line. (C) 2015 Elsevier Ltd. All rights reserved.
• Process for preparing alpha-carboxamide derivatives
  申请人：Convergence Pharmaceuticals Limited

  公开号：EP2477964B1

  公开（公告）日：2015-02-11